Neurizon Therapeutics Limited, a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has strengthened its executive management team with three key appointments:

• Ms. Kathryn Williams as Chief Regulatory Officer (CRO)
• Dr. Jeffrey M. Brown as Chief Scientific Advisor (CSA)
• Dr. Chris Freitag as Chief Medical Advisor (CMA)

These appointments provide the Company with broader expertise in regulatory affairs, clinical development and commercialization, and will assist in accelerating Neurizon’s stated strategy to advance its lead drug candidate, NUZ-001’s clinical development pathway, secure regulatory approvals, expand the pipeline in neurodegenerative diseases and optimize future market access.

The combined expertise of Williams, Brown, and Freitag will assist in the Company’s near-term focus to lift the clinical hold for NUZ-001’s IND application to facilitate entry into the HEALEY ALS Platform Trial in H2 CY2025.

Chief Regulatory Officer, Kathryn Williams

Williams is a regulatory affairs executive with over 20 years of industry experience. She has a proven track record developing and executing global regulatory strategies in major jurisdictions, including the U.S. FDA, European EMA and Australian TGA. Williams is considered a global regulatory specialist, navigating expedited approval pathways and securing orphan drug designations for rare diseases and novel therapies.

Most recently, Williams held the position of Vice President of Regulatory Affairs at Clarity Pharmaceuticals Limited. Throughout her career, Williams has held leadership positions in notable companies, including Merck, Sandoz, Sanofi and Genzyme.

The Company will leverage her background in pharmaceutical regulation and health economics to ensure Neurizon’s clinical programs are well-positioned for regulatory, commercial, and reimbursement success. As CRO, she will oversee regulatory engagement, Chemistry Manufacturing Control (CMC) alignment, and quality compliance systems, while leading regulatory strategy across all development stages. Her focus will be on securing Investigational New Drug (IND) status, Fast Track, Breakthrough Therapy, and Orphan Drug designations, as well as optimizing regulatory efforts to support accelerated approval across multiple jurisdictions for NUZ-001.

Chief Scientific Advisor, Jeffrey M. Brown

Brown brings extensive drug development experience, scientific leadership, and commercial acumen, in the development of new treatments for neuropsychiatric and neurodegenerative diseases. Over his two-decade career, he has overseen multiple neurology programs from early discovery through IND-enabling studies. This includes select programs in pain, neuropsychiatry, and Huntington’s diseases currently in clinical trials.

Brown’s scientific understanding of neuropsychiatric and neurodegenerative disease pathways has led to executive leadership roles in global biopharmaceutical companies such as Amgen, Pfizer, Bristol-Myers Squibb, Alexion, Wave, Voyager, and Deep genomics, managing R&D organizations, expanding pipeline and platform capabilities, and nurturing partnering and commercial discussions.

His expertise in drug discovery and defining product development opportunities will be instrumental in expanding and advancing the reach of Neurizon’s therapeutic pipeline in neurodegenerative diseases. Brown currently serves on the Board of Directors of the Huntington’s Disease Society of America.

Chief Medical Advisor, Chris Freitag

Freitag is a medical doctor with nearly 30 years of combined medical and pharmaceutical experience, with a strong focus on oncology and rare diseases. His early career in clinical practice was followed by senior roles at Roche, Shire, BTG, and Debiopharm, where he led clinical programs across biologics, small molecules, and medical devices.

More recently, Freitag served as Chief Medical Officer or strategic advisor to several emerging biotech companies, primarily in neurodegenerative diseases, pediatric rare diseases (myopathies), and oncology.

Freitag is already a valuable member of Neurizon’s Scientific Advisory Board (SAB) and possesses intricate knowledge of the clinical safety and efficacy profile of NUZ-001. He has served as the medical monitor (MM) for Neurizon’s successful Phase 1 MEND study and is currently the MM for the Open Label Extension (OLE) study for NUZ-001. His increased involvement as CMA will significantly benefit the Company’s clinical development program for NUZ-001, ongoing trial designs, and medical affairs. Freitag’s experience will be crucial in guiding NUZ-001 through regulatory interactions, Point of Care considerations, and achieving regulatory approval.